Episode Details

Fluvoxamine, a common antidepressant, significantly reduces fatigue in long COVID patients, according to a new study. The drug outperformed a placebo in a trial involving 399 adults, offering hope for the 65 million people worldwide affected by long COVID. While metformin, a diabetes drug, didnt help fatigue, fluvoxamine showed promising results, with a 99% chance of working better than nothing and improving quality of life scores. The study, conducted in Brazil with support from U.S. and Canadian institutions, is set to publish full results on March 31st, potentially paving the way for affordable, effective treatment options.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/3e9f95694ca52ecc